In Vivo Testing and Statistics Core

体内测试和统计核心

• 批准号: 7222675
• 负责人: DONNA M. BOULEY
• 金额: $ 18.45万
• 依托单位: STANFORD UNIVERSITY
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/7222675
• 关键词: antineoplastics; biomedical facility; blood chemistry; data management; drug screening /evaluation; histopathology; human tissue; laboratory mouse; neoplasm /cancer; neoplasm /cancer radiation therapy; neoplasm /cancer therapy; neoplastic cell; nonhuman therapy evaluation; statistical service /center; statistics /biometry; tissue /cell preparation; tissue /organ preservation; tissue resource /registry

This core has three goals. The first is to provide expert and uniform in vivo evaluation of the compounds that are judged worthy of evaluation from in vitro testing. This core will also provide all of the normal tissue toxicology testing. All the tumor testing will be performed with the HT29/Ak human tumor transplanted into nu/nu mice. The normal tissue toxicology testing will be performed with the nu/nu mice beating the HT29 tumor (because of the possibility of active drug "leaking" into the vasculature from the tumor), and with CD1 mice (without tumors). The second goal of the project is to provide a centralized cell line, medium and serum bank to each project to ensure uniformity as much as possible between the test systems used by all of the projects. The Core will also perform the serum testing and mycoplasma testing of the cell lines used by all the projects. The third goal is to provide statistical and database support for all of the projects in the Program Project.

这个核心有三个目标。首先是对通过体外测试判断值得评估的化合物提供专家和统一的体内评估。该核心还将提供所有正常组织毒理学测试。所有肿瘤测试都将使用移植到 nu/nu 小鼠体内的 HT29/Ak 人类肿瘤进行。正常组织毒理学测试将使用击败 HT29 肿瘤的 nu/nu 小鼠（因为活性药物可能从肿瘤“渗漏”到脉管系统中）和 CD1 小鼠（无肿瘤）进行。该项目的第二个目标是为每个项目提供集中的细胞系、培养基和血清库，以 尽可能确保所有项目使用的测试系统之间的一致性。核心还将对所有项目使用的细胞系进行血清检测和支原体检测。第三个目标是为计划项目中的所有项目提供统计和数据库支持。